ASC-240-002

Phase I, open-label, sequential-group, three-cohort study to evaluate the pharmacokinetic profile, the safety and the tolerability of a single injection of lanreotide Extended-Release Formulation (ERF) at doses of 120 mg and 240 mg in healthy volunteers

The undersigned hereby declares his/her consent to performance of the clinical study in compliance with regulations as laid down in this clinical study protocol, in the Declaration of Helsinki and in the ICH-GCP Guideline and applicable national laws and regulations. Changes to this protocol require written agreement of both investigator and sponsor.

The Investigator has acquainted himself with the results of the pharmacological and toxicological studies of the investigational product and the results of other studies as described in the investigator’s brochure or other appropriate information.